203 related articles for article (PubMed ID: 30296806)
1. Review of Clinical Pharmacokinetics of Avibactam, A Newly Approved non-β lactam β-lactamase Inhibitor Drug, In Combination Use With Ceftazidime.
Giri P; Patel H; Srinivas NR
Drug Res (Stuttg); 2019 May; 69(5):245-255. PubMed ID: 30296806
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.
Sy SKB; Zhuang L; Sy S; Derendorf H
Clin Pharmacokinet; 2019 May; 58(5):545-564. PubMed ID: 30097887
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
[TBL] [Abstract][Full Text] [Related]
4. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
MacGowan A; Tomaselli S; Noel A; Bowker K
J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276
[TBL] [Abstract][Full Text] [Related]
5. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
6. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA
Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506
[TBL] [Abstract][Full Text] [Related]
7. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
Shirley M
Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
[TBL] [Abstract][Full Text] [Related]
8. A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria.
Kristoffersson AN; Bissantz C; Okujava R; Haldimann A; Walter I; Shi T; Zampaloni C; Nielsen EI
J Antimicrob Chemother; 2020 Feb; 75(2):400-408. PubMed ID: 31670804
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment.
Merdjan H; Tarral A; Das S; Li J
J Clin Pharmacol; 2017 Feb; 57(2):211-218. PubMed ID: 27402250
[TBL] [Abstract][Full Text] [Related]
10. Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia.
Das S; Li J; Riccobene T; Carrothers TJ; Newell P; Melnick D; Critchley IA; Stone GG; Nichols WW
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670413
[TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies.
Merdjan H; Rangaraju M; Tarral A
Clin Drug Investig; 2015 May; 35(5):307-17. PubMed ID: 25813217
[TBL] [Abstract][Full Text] [Related]
12. Monte Carlo Simulation Methodologies for β-Lactam/β-Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments.
Kidd JM; Stein GE; Nicolau DP; Kuti JL
J Clin Pharmacol; 2020 Feb; 60(2):172-180. PubMed ID: 31423601
[TBL] [Abstract][Full Text] [Related]
13. Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model.
Barber KE; Pogue JM; Warnock HD; Bonomo RA; Kaye KS
J Antimicrob Chemother; 2018 Sep; 73(9):2405-2410. PubMed ID: 29939267
[TBL] [Abstract][Full Text] [Related]
14. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.
van Duin D; Bonomo RA
Clin Infect Dis; 2016 Jul; 63(2):234-41. PubMed ID: 27098166
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of Ceftazidime-Avibactam in Two Patients With KPC-Producing Klebsiella pneumoniae Bacteremia and Renal Impairment.
Veillette JJ; Truong J; Forland SC
Pharmacotherapy; 2016 Nov; 36(11):e172-e177. PubMed ID: 27716983
[TBL] [Abstract][Full Text] [Related]
16. Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia.
Das S; Zhou D; Nichols WW; Townsend A; Newell P; Li J
Eur J Clin Pharmacol; 2020 Mar; 76(3):349-361. PubMed ID: 31836928
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older.
Franzese RC; McFadyen L; Watson KJ; Riccobene T; Carrothers TJ; Vourvahis M; Chan PLS; Raber S; Bradley JS; Lovern M
Clin Pharmacol Ther; 2022 Mar; 111(3):635-645. PubMed ID: 34687548
[TBL] [Abstract][Full Text] [Related]
18. The β-Lactams Strike Back: Ceftazidime-Avibactam.
Zasowski EJ; Rybak JM; Rybak MJ
Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.
Berkhout J; Melchers MJ; van Mil AC; Seyedmousavi S; Lagarde CM; Nichols WW; Mouton JW
Antimicrob Agents Chemother; 2015 Apr; 59(4):2299-304. PubMed ID: 25645843
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections.
Buckman SA; Krekel T; Muller AE; Mazuski JE
Expert Opin Pharmacother; 2016 Dec; 17(17):2341-2349. PubMed ID: 27758148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
